<DOC>
	<DOCNO>NCT02162563</DOCNO>
	<brief_summary>Colorectal cancer patient initially unresectable liver-only metastasis may cure downsize metastasis neoadjuvant systemic therapy . However , optimal neoadjuvant induction regimen define , consensus exist criterion resectability . In study colorectal cancer patient initially unresectable liver-only metastasis , prospectively confirm expert panel accord predefined criterion , test RAS BRAF tumor mutation status . Patients RAS mutant tumor randomise doublet chemotherapy ( FOLFOX FOLFIRI ) plus bevacizumab ( schedule 1 ) , triple chemotherapy ( FOLFOXIRI ) plus bevacizumab ( schedule 2 ) . Patients RAS wildtype tumor randomize doublet chemotherapy ( FOLFOX FOLFIRI ) plus either bevacizumab ( schedule 1 ) panitumumab ( schedule 3 ) . Patient image review resectability central panel , consist least one radiologist three surgeon every assessment . Central panel review perform prior randomization well treatment , describe protocol .</brief_summary>
	<brief_title>Treatment Strategies Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases</brief_title>
	<detailed_description>Patients stratify resectability liver metastasis ( potentially resectable versus permanently unresectable ) , serum lactate dehydrogenase ( LDH ) ( normal versus abnormal ) , BRAF mutation status ( wildtype versus mutate ) , type neoadjuvant chemotherapy ( FOLFIRI versus FOLFOX ) hospital registration . Patients RAS wildtype tumor randomise FOLFOX FOLFIRI ) plus either bevacizumab panitumumab . The choice FOLFOX FOLFIRI discretion local investigator , however , treatment restrict regimen specify protocol . Patients RAS mutate tumor randomize FOLFOX/ FOLFIRI ( investigator choice ) plus bevacizumab 5FU , irinotecan , oxaliplatin ( FOLFOXIRI ) plus bevacizumab . Patients evaluate every 8 week CT scan disease status . The assigned systemic treatment continue least 6 month earlier case resectability , progression disease , unacceptable toxicity , patient refusal . If 6 month panel conclude patient still resectable , highly unlikely resectability achieve . Therefore chemotherapy regimen may reconsider 6 month treatment . These patient continue target drug combination chemotherapy , chemotherapy may alter less toxic schedule fluoropyrimidine monotherapy . The targeted drug continue progression unacceptable toxicity . In patient become resectable undergo secondary surgery liver metastasis , total duration preoperative postoperative treatment together 6 month , chemotherapy schedule administer accord assign treatment arm . However patient target drug ( bevacizumab panitumumab ) continue surgery .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically proven colorectal cancer Unresectable metastasis confine liver accord CT scan , obtain ≤ 2 week prior registration . Unresectability confirm panel . Patients small ( ≤ 1 cm ) extrahepatic lesion clearly suspicious metastasis eligible . Adequate tumor tissue available central assessment RAS/BRAF mutation statusWHO performance status 01 ( Karnofsky performance status ≥ 70 ) Age ≥ 18 year No contraindication liver surgery Resectable primary tumor , still situ Adequate organ function , determine normal bone marrow function ( Hb ³ 6.0 mmol/L , absolute neutrophil count ³ 1.5 x 109/L , platelet ³ 100 x 109/L ) , renal function ( serum creatinine ≤ 1.5x ULN creatinine clearance , Cockroft formula , ³ 30 ml/min ) , liver function ( serum bilirubin ≤ 2 x ULN , serum transaminase ≤ 5x ULN ) Life expectancy &gt; 12 week Expected adequacy followup Written inform consent Extrahepatic metastasis ( extrahepatic lesion ≤ 1 cm clearly suspicious metastasis include ) Unresectable primary tumor Serious comorbidity condition prevent safe administration study treatment ( include systemic treatment surgery ) Major cardiovascular event ( myocardial infarction , severe/unstable angina , congestive heart failure , CVA ) within 12 month registration Uncontrolled hypertension , unsatisfactory blood pressure control ≥3 antihypertensive drug Previous systemic treatment metastatic disease ; previous adjuvant treatment allow complete ≥ 6 month prior registration Previous surgery metastatic disease Previous intolerance study drug adjuvant set Pregnant lactate woman Second primary malignancy within past 5 year exception adequately treat situ carcinoma organ basal cell carcinoma skin Any concomitant experimental treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Colorectal cancer</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Anti-EGFR</keyword>
	<keyword>Liver metastasis</keyword>
	<keyword>R0 R1 liver resection</keyword>
	<keyword>Resectability liver</keyword>
	<keyword>Liver expert panel</keyword>
</DOC>